SCHEMBL537832

SCHEMBL537832

CCOC(=O)CCCN(Cc1ccc(OC)cc1)c1nc(SC)nc(Cl)c1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ L3MBTL1 Q9Y468 4/20 0.40
▸ HTT P42858 2/20 0.40
▸ LMNA P02545 5/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ AGTR1 P30556 1/20 0.36
▸ AGTR2 P50052 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ P2RX3 P56373 1/20 0.36
▸ PPARG P37231 1/20 0.35
▸ MEP1B Q16820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537450 0.93 MAPT (0.40) MAPTSMN1; SMN2L3MBTL1HTTLMNA
SCHEMBL13146339 0.81 MAPT (0.37) MAPTSMN1; SMN2L3MBTL1HTTLMNA
SCHEMBL537640 0.79 PPARG (0.42) MAPTSMN1; SMN2L3MBTL1HTTLMNA
SCHEMBL13145803 0.78 MAPT (0.37) MAPTSMN1; SMN2L3MBTL1HTTLMNA
SCHEMBL13131434 0.76 PPARG (0.43) MAPTSMN1; SMN2L3MBTL1HTTMAPK1
SCHEMBL13145998 0.74 PPARG (0.45) MAPTSMN1; SMN2L3MBTL1HTTLMNA
SCHEMBL16446548 0.74 ALDH1A1 (0.46) MAPTSMN1; SMN2HTTLMNAMAPK1
SCHEMBL14407177 0.70 MAPT (0.35) MAPTSMN1; SMN2L3MBTL1HTTLMNA
SCHEMBL538288 0.67 THRB (0.43) MAPTSMN1; SMN2L3MBTL1LMNAMAPK1
SCHEMBL31289829 0.66 TARBP2 (0.43) MAPTSMN1; SMN2HTTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 — — US disclosed
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 — — EP disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 — — WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 MAPT 2947/4885SMN1; SMN2 2524/4885L3MBTL1 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback